LifeStance Health (US:LFST)2021-08-12 01:14Financial Performance - Revenue for Q2 2021 was $160.5 million, a 91% increase year-over-year compared to $84.0 million in Q2 2020[7] - Adjusted EBITDA for Q2 2021 was $14.5 million, a 39% increase year-over-year compared to $10.5 million in Q2 2020[7] - The company has a strong balance sheet with a cash position of $276 million[7] - TTM (Trailing Twelve Months) Revenue is $524 million[8] Growth and Expansion - Total clinicians reached 3,975, up 94% year-over-year, with 674 net clinician additions in Q2 2021[7] - The company operates in 31 states with 450+ centers[10, 16, 18] - 35 de novo centers were opened in Q2 2021, part of 183 opened since inception[16] - 10 acquisitions were completed in Q2 2021, part of 64 acquisitions completed since inception[16] Market and Strategy - The company is well-positioned for continued market share gains in the $116 billion mental health market[10] - The company estimates the total addressable market (TAM) will grow to $215 billion by 2025, representing a 14% CAGR (Compound Annual Growth Rate)[17] Social Responsibility - The LifeStance Health Foundation was established with an initial endowment of $10 million[7, 13]